Clinical trials: Moderate Dementia
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.
Healthy, Alzheimer Disease
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
Up to 20 subjects will receive an injection with [11C]-UCB-J followed by a PET scan on Days 1 and 28
- Trial name
- NCT03577262
- Testing
- [11C]-UCB-J
- Where
- 3 sites in Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Dementia
The Effect of Digital Reminiscence Therapy on People With Mild and Moderate Dementia
In the post-epidemic era, it is necessary to develop support programs for families with dementia in empirical care. The reminiscence therapy was adopted by patients with mild and moderate dementia those intervention have had good…
- Trial name
- NCT05341271
- Testing
- Experimental: digital reminiscence group (DRG), Experimental: general reminiscence group (GRG)
- Where
- Taiwan
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- National Taipei University of Nursing and Health Sciences
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Dementia, Moderate Dementia
The Effects of a Park Visit Program on Individuals With Dementia and Their Caregivers
The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers.
- Conditions
- Mild Dementia, Moderate Dementia, Alzheimer Disease
- Trial name
- NCT05527587
- Testing
- Nature Connections Intervention
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Alzheimer's Disease
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
- Trial name
- NCT00329082
- Testing
- LY2062430
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cognitive Impairment, Mild, Dementia, Mild
Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases and Their Primary Caregivers
Our main goal is to test a web platform accessible by computers, smartphones and tablets, addressed specifically to caregivers and people with mild cognitive deterioration or mild to moderate dementia providing added value…
- Trial name
- CAREGIVERSPRO (NCT03536975)
- Testing
- Platform
- Where
- 2 sites in France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Mild Dementia
Gait, cOgnitiOn & Decline (GOOD)
The main objective of the GOOD initiative was to determine which spatio-temporal gait parameters and/or combination(s) of spatio-temporal gait parameters best differentiate between cognitively healthy individuals (CHI), patients…
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Healthy
- Trial name
- NCT02350270
- Testing
- gait and cognitive testing
- Where
- France
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
This is a research study that aims to examine whether Veterans with mild Traumatic Brain Injuries are at risk for dementia by studying their memory, brain wave activity, brain structure and proteins that can be elevated after…
- Conditions
- Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
- Trial name
- NCT04124029
- Testing
- No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Late Onset Alzheimer
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly.
- Trial name
- NINDS-AIREN (NCT02007291)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Dementia, Dysphagia
Family Caregiver Online Survey (Dementia and Swallowing Difficulties)
The Family Caregiver Survey is a one-time, 30-minute, online survey for people living with and caring for a family member with dementia.
- Conditions
- Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular
- Trial name
- NCT06471660
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Alzheimer Disease, Dementia
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05527288
- Testing
- Drug: [18F]florbetaben
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Dementia
A Study to Compare Genetic Variations of IGF-I and IGF-II
The purpose of this study is to determine if insulin-like growth factors (IGF) play a role in the development of dementia, specifically Alzheimer's disease (AD).
- Trial name
- NCT01329523
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Avera McKennan Hospital & University Health Center